News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kineta Inc. Announces Regulatory Clearance to Initiate a Phase 1 Clinical Trial for ShK-186


8/21/2012 9:34:38 AM

SEATTLE--(BUSINESS WIRE)--Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel. Kineta’s program is the first Kv1.3-specific inhibitor advanced into the clinic, a key milestone in the industry’s race to develop an immune-sparing therapy for a spectrum of diseases that includes Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Lupus (SLE).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES